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Abstract: The employment of monoclonal antibodies (Mabs) to identify disease-associated 
biomarkers in  clinical  samples  represents  the underlying principle for  many diagnostic 
tests. To date, these have been principally developed for protein targets with few reported 
applications for lipids due to their hydrophobicity and poor immunogenicity. Oxysterols 
represent  a  family  of  lipids  implicated  in  diverse  human  diseases  where  Mab-based 
detection assays could have a profound effect on their utility as clinical biomarkers. These 
are usually identified in patients’ samples by mass- spectrometry based approaches. Here, 
we  describe  an  antibody  phage-library  based  screening  methodology  for  generating  a 
recombinant  monoclonal  antibody  (RAb)  targeting  the  oxysterol-15-ketocholestane  
(15-KA), a lipid implicated in multiple sclerosis and Autoimmune Encephalomyelitis (EAE). 
The antibody is highly specific for 15-KA and shows little or no binding activity for other 
closely related oxysterols. We employ RAb2E9 to address the controversy over whether 
15-KA is a true biomarker for MS/EAE and show that 15-KA is undetectable in serum 
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taken  from  mice  with  EAE  using  antibody  based  detection  methodologies;  a  finding 
confirmed by mass-spectrometry analysis. This study demonstrates the technical feasibility 
of using phage display to isolate highly specific antibodies against poorly immunogenic, 
small molecule lipids. 
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1. Introduction 
Monoclonal antibodies are routinely employed in biomarker identification and quantitation as vital 
components of radioimunoassays, enzyme linked immunosorbent assays (ELISA), immunocytopathology 
and flow cytometry assays for in vitro and in vivo diagnoses, imaging and immunotherapy [1]. The use 
of antibodies as diagnostic tools has been limited thus far to mainly protein antigens. For diseases 
where  lipids  are  implicated  and  would  make  ideal  biomarkers,  the  employment  of  antibodies  is 
restricted to detecting anti-lipid IgGs but not the lipid antigens themselves. The detection of anti-lipid 
IgGs is  associated with autoimmune inflammatory  diseases  such as systemic lupus erythematosus 
(SLE),  rheumatoid  arthritis  and  systemic  sclerosis, where  antiphospholipid  syndrome  (APLS)  is  a 
common complication [2]. An antibody-based detection of lipid antigens would potentially form a 
complementary approach aimed at detecting the relevant lipid-based parameters at an earlier stage in 
disease than the antibody responses they engender.  
Oxysterols are reported to be altered in several neurodegenerative and demyelinating diseases such 
as Alzheimer’s disease (AD) and multiple sclerosis (MS) [3]. The characterization of oxysterols as 
bona fide ligands for the nuclear receptor, liver x receptor (LXR) [4], has augmented their potential as 
biomarkers for these common neurodegenerative disorders [5]. Some controversy exist however as to 
the identification of oxysterol 15-ketocholestane (15-KA) in MS [6]. The involvement of 15-KA in 
MS was first suggested through serum and cerebrospinal fluid anti-lipid IgG characterization on lipid 
microarrays [7]. Administration of 15-KA amongst a group of oxidized cholesterol derivatives to mice 
in the MS animal model experimental autoimmune encephalomyelitis (EAE) exacerbated the disease [8] 
and detection of a number of oxysterols including 15-KA has been made in both MS and EAE [9]. 
However, a recent study was unable to support this association in both MS patients and EAE mice [6] 
and thus the true potential of 15-KA as an MS biomarker remains controversial. 
As biological analytes, oxysterols are challenging to measure based on their low abundance against 
a high background of cholesterol. Mass-spectrometry is the analytical method of choice either in the 
GC-MS or LC-MS format, but requires extensive sample preparation to help resolve the oxysterols 
from other more abundant lipids [10–12]; and this has been held responsible for controversy that 
currently exists over the identification of the 15-KA in MS [13]. Antibody based detection methods 
with sterol-specific antibodies could overcome these challenges, as this would allow detection in a 
complex lipid matrix.  
We describe here the generation of 15-KA specific antibody to broaden the range of assays that can 
be utilized to detect and quantify 15-KA. Traditionally, monoclonal antibodies against small lipid or 
other biomolecules are difficult to generate as they are poor immunogens that do not engender good Int. J. Mol. Sci. 2012, 13  4939 
 
antibody responses in immunized rodents and often require conjugation to a protein carrier to produce 
a sufficiently good immune response for hybridoma generation [14,15]. Indeed our efforts to raise 
antibodies  against  unconjugated  15-KA  using  the  classical  mouse  hybridoma  techniques  were 
unsuccessful. We therefore selected an antibody-generating methodology that avoided the requirement 
for generating an immune response, which was based on the in vitro screening of a non-immunized 
recombinant human Fab phage library. From this library, we were able to isolate a RAb specific for 
15-KA. This antibody is highly specific for 15-KA and shows little or no binding activity to other 
closely  related  oxysterols.  Using  this  antibody,  we  then  sought  to  address  the  controversial 
identification of 15-KA as a biomarker in EAE/MS. 
2. Results and Discussion 
2.1. Panning the Fab-phage Library with 15-KA 
Previous  studies  had  shown  that  under  pathological  conditions  such  as  atherosclerosis,  the 
presentation of oxysterols may differ from the normal physiological state and may coalesce into lipid 
microcrystals through a cycle of aggregation and inflammation [16]. Murine monoclonal antibodies 
previously generated against cholesterol have also been shown to bind crystalline forms of the lipid 
generated by evaporation from solution in ethanol [17]. In light of these previous findings and the 
difficulty of dissolving a highly non-polar lipid in an aqueous solution, we decided to pan the phage 
library against 15-KA microcrystals coated onto a solid support immunotube by evaporation from an 
ethanol solution. 
The  human  phage  antibody  library  underwent  5  rounds  of  panning  with  the  enriched  phage 
antibodies  assayed  for  binding  activity  after  each  panning  step.  Enrichment  for  15-KA-specific 
polyclonal antibodies was observed from the 4th round of panning onwards. After the final pan against 
15-KA, Fabs from 380 single colonies were tested for their ability to bind to 15-KA by ELISA and 
five clones selected based on their unique combination of heavy and light variable chain sequences as 
determined by BstN1 restriction digest and Sanger sequencing. The CDR3 amino acid sequences and 
germline variable genes used are given in Table 1. These five clones were subsequently converted to 
human IgG1s and expressed in mammalian tissue culture as full length recombinant antibodies.  
Table 1. Sequences of CDR3 for Fab of phage isolated against 15-KA. 
Clone  VL CDR3  VL gene  VH CDR3  VH gene 
1D2  GTHWPYTFGQG  KV2D-28  GVVGSMDV  HV1-18 
2B5  ALQSPFTFGPG  KV2D-28  PPDNRGFYFDF  HV1-3 
2E9  GTHWPYTFGQG  KV2D-28  ERAVTNYYYYYGMDV  HV1-3 
3D2  ALQTPSFGGG  KV2D-28  ETYSSSWYAPKYFDY  HV1-3 
3E2  ALRSPSFGPG  KV2D-28  TPRWLQNIPNDY  HV3-21 
2.2. Specificity of Anti-15-KA Human IgG for Crystalline 15-KA 
Given our desire to generate antibodies against 15-KA microcrystals, we carried out microscopic 
examination of ethanol-evaporated 15-KA to confirm crystal formation. As binding of the antibody 
may  be  specific  to  the  type  of  crystal  structure  and  not  the  specific  oxysterol,  we  concurrently Int. J. Mol. Sci. 2012, 13  4940 
 
examined  a  series  of  related  oxysterols  dissolved  in  ethanol  and  evaporated  in  the  same  manner. 
Microscopic examination showed that each oxysterol either formed a unique crystalline microstructure 
or a monolayer after ethanol evaporation (Figure 1A). 
Having  confirmed the  microcrystal  structure of 15-KA, the 5 unique  IgG were then tested for 
binding affinity against these oxysteols including 15-KA by ELISA (Figure 1B). All five clones had 
similar specific binding activity for 15-KA and did not bind any other oxysteol in spite of their close 
similarity in molecular structure (Figure 1A). We show a representative binding profile of the antibody 
with the strongest binding for 15-KA (RAb2E9) to this panel of oxysterols including 7-ketocholesterol 
and 15-ketocholestene (Figure 1C). Thus, the monoclonal human anti-15-KA IgG only binds to a 
higher order crystalline form of 15-KA but not to the crystalline forms of other oxysterols. This could 
be due either to the difference in crystal structure or the different molecular structure of the oxysterols 
or a combination of both. 
Figure 1. (A) Chemical structures of cholesterol, 15-KA, and a selected panel of oxysterols 
that are closely related to 15-KA. Light micrographs of crystals of pure anhydrous sterols 
dried from ethanol were taken at magnification of 40X. Scale bar equals 30 μm. (B) Analysis 
of unique RAb isolate from panning against 15-KA following conversion to human IgG1. 
Coating of the microtitre plates was at 1 µg per well and binding was measured by ELISA. 
(C) Analysis of specificity of antibody RAb2E9. Cholesterol, 15-KA and the indicated 
panel of oxysterols were coated on microtitre plates at 1µg per well. Reactivity of RAb2E9 
to the coated sterols was measured using ELISA.  
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Figure 1. Cont.  
 
2.3. Sensitivity of Human Anti-15-KA IgG 
To determine the sensitivity of the RAb2E9 for 15-KA, the antigen (15-KA) was titrated from  
2.5 µg/mL to 0.005 µg/mL and crystal formation observed microscopically (Figure 2A). RAb2E9 
exhibited good binding activity across the range of concentrations and was able to detect reliably down 
to  10  ng/mL  using  ELISA  (Figure  2B).  Interestingly,  the  crystal  structure  of  15-KA  varies  with 
concentration  and  at  0.156  µg/mL  resembles  the  structure  of  the  oxysterol  7α-hydroxycholesterol  
(7α-HO)  included  in  the  figure  1A  (Figure  2A).  The  fact  that  RAb2E9  binds  15-KA  at  this 
concentration strongly to 15-KA but not 7α-HO suggests that the specificity is due to the differences in 
oxysterol molecular structure. In addition, the ability of RAb2E9 to bind 15-KA crystals of varying 
microstructures indicates that crystal structure does not determine antibody specificity. The ability of 
this antibody to distinguish such minute difference in oxysterol structure (a loss of a keto group on the 
15-C and a gain of a hydroxyl on the nearby 7-C) is surprising. 
2.4. Detection of 15-KA in EAE Mouse Serum with RAb2E9 
It was reported by Farez and colleagues that 15-KA is present in MS patient serum and EAE mouse 
serum in concentration ranges from 1.2 µg/mL to 300 ng/mL [9]. Based on our in vitro analyses, these 
are  clearly  within  the  detection  limits  of  RAb2E9  in  ELISA  and  combined  with  the  antibody’s 
exquisite specificity should allow detection in serum without the complex manipulations needed for 
mass spectrometry. To ascertain the feasibility for detecting 15-KA in serum, we tested the detection 
of 15-KA in murine serum spiked with 15-KA from 1 µg/mL to 50 ng/mL following extraction of the 
lipid  fraction  and  coating  on  microtitre  plates  for  ELISA.  RAb2E9  was  able  to  detect  15-KA  in 
samples spiked with 1 µg/mL to 100 ng/mL of 15-KA (Figure 3A). Analysis with LC-MS affirmed the 
recovery of 15-KA from the same samples (down to concentrations of 100 ng/mL) (Figure 3B). 
EAE mice immunized with MOG35-55 were monitored for the development of total hind limb 
paralysis as a marker for severe disease. At this stage, mice were euthanized and blood samples collected 
by cardiac puncture. Total lipid was extracted from the EAE mouse serum together with spiked and 
unspiked normal mouse serum as positive and negative control respectively and the presence of 15-KA 
analyzed  by  ELISA  with  RAb2E9  (Figure  3C).  Despite  the  positive  signal  in  the  spiked  sample,  
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15-KA was  not  detected in  the EAE mouse serum. Moreover, similar  to  the study  performed  by 
Bjorkhem and colleagues [6], no detectable levels of 15-KA were found by LC-MS (data not shown). 
Figure 2. (A) Light micrographs of 15-ketocholestane crystals over a concentration range 
from 2.5 µg/mL to 0.005 µg/mL after coating in 96-microtitre wells. Images were taken at 
40 ×  magnification. Scale bar equals 50 μm. (B) Titration of 15-ketocholestane against 
RAb2E9 using direct ELISA. The plate, which was used for microcrystal imaging, was 
then processed for ELISA with 1 µg/mL of Rab2E9 antibody. (C) Dose dependent binding 
of RAb2E9 with 15-KA. 15-KA was coated at 20 ng/well and the ELISA performed with 
the indicated concentrations of RAb2E9. 
 
Figure 3. (A) Spiking of mouse serum where 15-KA was dissolved in mouse serum at 
indicated concentrations and mixed overnight, then extracted with cholorofrom:methanol. 
The extracted samples  were  coated onto  the  ELISA plates  and detected with  RAb2E9 
antibody. (B) Mass-spectrometry analysis of 15-KA recovered from the spiked samples.  
(C) Lipids from spiked serum, EAE and control mouse blood serum were extracted and 
analyzed by ELISA with RAb2E9. 
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2.5. Discussion 
With the important exception of glycolipids, relatively few antibodies that recognize specific lipids 
have been described. Little is known about the precise molecular requirement for successful generation 
of antibodies against lipids either in terms of their presentation during immunization in vivo or their 
selection in vitro. However, with the increasing availability of pure, synthetic, and stable lipids, we 
now have the opportunity to systematically screen these stable antigens against a non-immune phage 
library. As the phage display technique bypasses the use of animals and requires a shorter time frame 
relative to the hybridoma approach, it could be used to generate a whole class of novel tools for basic 
research  and  medical  diagnostics  with  applications  in  immunohistochemistry,  cytochemistry  and 
biochemistry. In this study, we show that it is possible to generate antibodies against non-immunogenic 
oxysterols  using  phage  display,  bypassing  the  need  of  conjugating  the  oxysterol  to  immunogenic 
epitopes or using adjuvants to enhance its immunogenicity. 
We characterized the monoclonal anti-15-KA antibody, RAb2E9, for its antigen-binding properties 
and found higher binding for crystalline 15-KA, suggesting its binding site is a three-dimensional 
molecular arrangement on the surface of the oxysterol crystal. This binding to the crystal could be via 
stereoselective supramolecular interactions with tertiary structural motifs that form part of the higher 
molecular structure of the 15-KA crystal. We can speculate that the epitope is governed by the position 
of the double bond and the ketone group within the B and D-ring of the sterol, as the antibody is 
specific for 15-KA and not for other oxysterols (with modification in the double bonds hydroxyl group) 
closely related to 15-KA. The RAb2E9 antibody exhibited a detection limit of 10 ng/mL for pure 
crystalline 15-KA, and 100 ng/mL for 15-KA extracted from spiked plasma samples. A few groups 
have  generated  antibodies  against  crystalline  cholesterol  using  the  classical  hybridoma  approach 
developed by Kö hler and Milstein [17,18], but only antibodies of the IgM isotype were generated due 
to the non-immunogenic nature of the antigen. However, our use of a Fab phage library allowed for 
engineering of the isotype of the fragment crystallizable region (Fc region) to IgG.  
Several  groups  have  studied  15-KA  in  the  context  of  multiple  sclerosis  (MS).  Kanter  et  al. 
identified anti-15-KA autoantibody from the cerebrospinal fluid derived from relapsing MS patients, 
and Farez et al. were able to detect 300 ng/mL of 15-KA in the serum of mice with EAE using  
LC-MS [7,9]. This finding has since been challenged, as separate studies were unable to verify the 
presence of oxysterols in MS patients’ sera relative to healthy controls and concluded that if present at 
all it would only be in trace amounts [6,13]. Discussion centered on this controversy has suggested that 
the need for extensive sample preparation to allow reduction of the cholesterol may be a cause of the 
discrepancy [13]. As RAb2E9 does not react to other oxysterols or cholesterol and has a functional 
range straddling the 15-KA concentration suggested to be present, we were able to perform analysis in 
crude lipid extracts of EAE serum without the need for excessive sample preparation. We could not 
detect 15-KA above that present in normal mouse serum with our antibody, a result we confirmed with 
mass-spectrometry. Given our limit of detection, this contrasts with the findings of Farez et al. [9]. 
Hence we are unable to confirm a role for 15-KA as a biomarker in EAE, the mouse model of MS.  
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3. Experimental Section 
3.1. Materials 
Cholesterol  (Chol)  and  its  derivatives,  15-ketocholestane  (15-KA),  15α-hydroxycholestane  
(15α-HA), 15β-hydroxycholestane (15β-HA), 15α-hydroxycholestene (15α-HE), 15β-hydroxycholestene 
(15β-HE), 15-ketocholestene (15-KE), 7-ketocholesterol (7-KO) and 7α-hydroxycholesterol (7α-HO) 
were  purchased  from  Avanti  Polar  Lipids,  Inc  (Alabama,  USA).  Goat  anti-human  (H+L  chain) 
horseradish peroxidase (HRP) conjugated secondary antibody was obtained from (Thermo Scientific 
Pierce, USA), ELISA plates and immunotubes from NUNC (Denmark). Anti M13-HRP conjugated 
secondary  antibody  was  purchased  from  Pharmacia  (Upsala,  Sweden).  All  other  analytical  grade 
chemicals were obtained from Sigma (St. Louis, MO, USA).  
3.2. Fab-phage Library Screening 
Library screening was performed using the non-immune human Fa- phage display library HX01 
(Humanyx  Pte  Ltd,  Singapore)  displayed  in  the  pCES1  vector  [19].  To  prepare  immunotubes  for 
panning, 15-KA was coated by adding the lipid in ethanol (200 μg/mL) and allowing the solvent to 
evaporate while the immunotubes were mixed horizontally overnight at room temperature. The coated 
immunotubes were then blocked in 2% skim milk (SM) in PBS for 1 h at room temperature prior to 
panning. Screening of the library was performed on antigen coated immunotubes essentially as described 
previously for protein antigens [20]. Briefly, Fab-phage were incubated with coated immunotubes for 
2 h at room temperature, followed by washing with PBS-T (0.1% Tween-20) to remove non-specific 
bound phage; specifically bound phage were then eluted by digestion with trypsin solution for 30 min 
at 37 ° C. Stringency of washing was increased during subsequent pans. Following six rounds of panning, 
enrichment was established using ELISA with the polyclonal Fab-phage preparations from each pan 
and individual clones were analyzed from the eluted phage of the pan showing the highest level of 
enrichment.  To  assess  the  uniqueness  of  positive  clones,  BstN1  restriction  digest  was  performed 
following PCR amplification of the Fab coding region and resolved on 3% agarose gel. Clones with 
similar patterns were grouped and the clone with the highest ELISA signal was converted to IgG for 
subsequent characterization. 
3.3. Conversion of Fab-phage to Human IgG1 
Distinct Fab-phage were converted to IgG1 by cloning the Fab containing fragment from pCES1 
into pCMV based vectors harboring the human constant regions for either the lambda or kappa light 
chain  and  IgG1  heavy  chain  separated  by  an  internal  ribosome  entry  sequence  [21].  Constructs 
encoding the Fab-IgGs  were transfected into human embryonic kidney  (HEK293) cells  by use  of 
lipofectamine 2000 (Invitrogen). Culture media was collected 72 h post transfection and fresh media 
was added to the cells and allowed to incubate for a further 72 h before collection. Secreted antibodies 
were  purified  using  recombinant  Protein-A  Sepharose  beads  (Thermo  Scientific  Pierce,  USA). 
Specificity of the antibodies was ascertained using ELISA with 15-KA, cholesterol and other oxysterols. 
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3.4. Oxysterol Crystal Imaging and ELISA 
Microtitre wells were coated with sterols dissolved in ethanol at the indicated concentration and the 
solvent  allowed  to  evaporate  overnight.  For  crystal  imaging,  images  were  then  captured  by  light 
microscopy. After imaging the wells were then blocked with 2% SM in PBS for 1 h at room temperature. 
100  µL  of  the  indicated  antibodies  were  then  added  for  2  h,  followed  by  HRP-conjugated  goat  
anti-human IgG (1:5000) in blocking buffer (1 h, room temperature). The reaction was visualized by 
the addition of 50 µL of chromogenic substrate TMB for 15 min, and was stopped with 100 µL of 
H2SO4. Absorbance was measured at 450nm. Plates were washed thrice with PBST between steps. 
3.5. Lipid Extraction from 15-KA Spiked and EAE Mouse Serum  
To  produce  spiked  serum  samples,  15-KA  was  dissolved  in  DMSO,  then  added  to  the  serum 
harvested from naï ve mice by cardiac puncture to reach the indicated concentrations and incubated 
overnight with mixing at 4 ° C. To produce EAE mouse serum, mice were injected subcutaneously with 
100 mg MOG35–55 and 1 mg heat-killed Mycobacterium tuberculosis H37RA (Invitrogen, Carlsbad, 
CA, USA) emulsified in complete Freund’s adjuvant. Pertussis toxin (200 ng in PBS; List Biological 
Laboratories, USA) was injected intra-peritoneally on days 0 and 2 after immunization. EAE clinical 
symptoms  were  assigned  scores  daily  as  follows:  0,  no  clinical  signs;  1,  loss  of  tail  tonicity;  2, 
impaired righting reflex; 3, partial hindlimb paralysis; 4, total hindlimb paralysis as described [22]. 
EAE mouse blood was collected via cardiac puncture and serum collected via centrifugation. The 
Institutional  Animal  Care  and  Use  Committee,  National  University  of  Singapore  approved  all 
experimental protocols on mice (IACUC number 018/11). The lipid fraction from serum was extracted 
using the standard chloroform:methanol extraction method as described [23], and diluted in 200 µL 
chloroform:methanol for LC-MS. The organic phase was collected and dried using a Speedvac. The 
extracted lipids were dissolved in 100 µL of ethanol for analysis by ELISA. 
3.6. Analysis of 15-KA Content Using High Performance LC-MS 
High performance liquid chromatography analysis was undertaken on an Accela system (Thermo 
Scientific,  USA).  Mass  spectrometry  analysis  was  undertaken  on  a  LTQ  Orbitrap  XL  instrument 
(Thermo Scientific) fitted with an electrospray ionisation source (ESI). Due to the unavailability of 
deuterated 15-KA, internal calibration was not possible. A calibration curve was therefore established 
by injection of 15-KA standard (Avanti Polar Lipids) at concentrations ranging from 10 ng/mL to  
50 μg/mL. This calibration curve was subsequently use for quantification of 15-KA in the samples.  
Standards and dried lipid extract samples were dissolved in chloroform:methanol 1:1 (v:v) and  
20 μL was used for LC on a Zorbax Eclipse XDB-C18 column (Agilent Technologies) as described 
previously  [24].  Mass  spectrometry  parameters  were  as  follows:  source  voltage  3.8  kV,  capillary 
voltage 36 V, tube lens 80, capillary temperature 300 ° C, sheath gas flow 40, auxiliary gas flow 10. 
The two main ions observed with 15-KA are at m/z 385.3 ([M + H-H2O]
+) and 403.4 ([M + H]
+), these 
two ions were monitored using single reaction monitoring scans for 15-KA detection in the samples. 
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4. Conclusions 
In  this  study  we  have  shown  the  development  of  a  RAb  against  the  oxysterol  15-KA,  a  lipid 
implicated in MS/EAE, using a phage-library based screening methodology. RAb2E9 exhibits little or 
no binding to closely related oxysterols and cholesterol, demonstrating its high specificity. We have 
also addressed the controversy over whether 15-KA is a true biomarker for MS/EAE using RAb2E9 
and shown that 15-KA is undetectable in serum taken from mice with EAE using antibody based 
detection methodologies; a finding confirmed by mass-spectrometry analysis. We are thus the first to 
report the generation and characterization of human monoclonal antibodies of the IgG1 isotype against 
an  oxysterol  15-ketocholestestane;  demonstrating  the  potential  of  Fab-phage  display  technique  to 
generate antibodies against crystalline forms of otherwise non-immunogenic lipids, such as oxysterols. 
This demonstrates the technical feasibility of using phage display to isolate highly specific antibodies 
against poorly immunogenic, small molecule lipids. 
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